DelveInsight’s “Her2 Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Her2 Negative Breast Cancer, historical and forecasted epidemiology as well as the Her2 Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Her2 Negative Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Her2 Negative Breast Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Her2 Negative Breast Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Her2 Negative Breast Cancer market.
Request for a Free Sample Report @ Her2 Negative Breast Cancer Market Forecast
Some facts of Her2 Negative Breast Cancer market report are:
- As per the 2020 report of the Global Cancer Observatory (Globocan), breast cancer was the most prevalent form of cancer worldwide in 2020. About 2,261,419 new cases of breast cancer were diagnosed in 2020. The incidence of breast cancer cases is expected to increase from 2,261,419 in 2020 to 3,025,471 new cases by 2040.
- In August 2022, the Food and Drug Administration (FDA) approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other regions of the body) HER2-breast cancer.
- In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC).
- Leading HER2 Negative Breast Cancer companies working in the market are Pfizer, Roche, Astrazeneca, Novartis, Eli Lilly, Merck, Eisai, Celgene, Chipscreen biosciences, OBI Pharma, PolyPhor, Syndax, Radius Health, Immunomedics and others.
Her2 Negative Breast Cancer Overview
Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC). Historically HR+ breast cancer has typically been treated with hormone therapies which is the cornerstone of treatment for patients with this disease while physicians have typically relied on chemotherapy for patients with triple negative breast cancer.
Learn more about Her2 Negative Breast Cancer, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market
Her2 Negative Breast Cancer Market
The Her2 Negative Breast Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Her2 Negative Breast Cancer market trends by analyzing the impact of current Her2 Negative Breast Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Her2 Negative Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Her2 Negative Breast Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Her2 Negative Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Her2 Negative Breast Cancer Epidemiology
The Her2 Negative Breast Cancer epidemiology section provides insights into the historical and current Her2 Negative Breast Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Her2 Negative Breast Cancer market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Her2 Negative Breast Cancer Epidemiology @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market
Her2 Negative Breast Cancer Drugs Uptake
This section focuses on the uptake rate of the potential Her2 Negative Breast Cancer drugs recently launched in the Her2 Negative Breast Cancer market or expected to be launched in 2019-2032. The analysis covers the Her2 Negative Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Her2 Negative Breast Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Her2 Negative Breast Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Her2 Negative Breast Cancer Pipeline Development Activities
The Her2 Negative Breast Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Her2 Negative Breast Cancer key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Her2 Negative Breast Cancer pipeline development activities @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market
Her2 Negative Breast Cancer Therapeutics Assessment
Major key companies are working proactively in the Her2 Negative Breast Cancer Therapeutics market to develop novel therapies which will drive the Her2 Negative Breast Cancer treatment markets in the upcoming years are Pfizer, Roche, Astrazeneca, Novartis, Eli Lilly, Merck, Eisai, Celgene, Chipscreen biosciences, OBI Pharma, PolyPhor, Syndax, Radius Health, Immunomedics and others.
Learn more about the emerging therapies & key companies @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-market
Her2 Negative Breast Cancer Report Key Insights
1. Her2 Negative Breast Cancer Patient Population
2. Her2 Negative Breast Cancer Market Size and Trends
3. Key Cross Competition in the Her2 Negative Breast Cancer Market
4. Her2 Negative Breast Cancer Market Dynamics (Key Drivers and Barriers)
5. Her2 Negative Breast Cancer Market Opportunities
6. Her2 Negative Breast Cancer Therapeutic Approaches
7. Her2 Negative Breast Cancer Pipeline Analysis
8. Her2 Negative Breast Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Her2 Negative Breast Cancer Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Her2 Negative Breast Cancer Competitive Intelligence Analysis
4. Her2 Negative Breast Cancer Market Overview at a Glance
5. Her2 Negative Breast Cancer Disease Background and Overview
6. Her2 Negative Breast Cancer Patient Journey
7. Her2 Negative Breast Cancer Epidemiology and Patient Population
8. Her2 Negative Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Her2 Negative Breast Cancer Unmet Needs
10. Key Endpoints of Her2 Negative Breast Cancer Treatment
11. Her2 Negative Breast Cancer Marketed Products
12. Her2 Negative Breast Cancer Emerging Therapies
13. Her2 Negative Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Her2 Negative Breast Cancer Market Outlook (7 major markets)
16. Her2 Negative Breast Cancer Access and Reimbursement Overview
17. KOL Views on the Her2 Negative Breast Cancer Market
18. Her2 Negative Breast Cancer Market Drivers
19. Her2 Negative Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting